One of our key objectives at Epilepsy Ireland is "to undertake, encourage, fund and communicate research into the causes of, cures for and management of epilepsy and into the social and psychological effects of the condition".
Researchers from the French National Health Insurance (CNAM) have just published a nationwide study of pregnancies ending between January 2011 and March 2015 to examine links between exposure to monotherapy with 10 different AEDs during the first two months of pregnancy and the risk of 23 specific major congenital malformations (MCMs). The study is published in the journal Neurology.
Congratulations to Sinéad Murphy on her appointment as a Registered Advanced Nurse Practitioner (RANP) for Women with Epilepsy. A RANP is a nurse who is an autonomous practitioner, responsible for advanced levels of decision-making and managing a patient caseload.
A new study led by FutureNeuro at RCSI has found a pattern of molecules that appear in the blood before a seizure happens. The researchers say that the discovery may lead to the development of an early warning system, which would enable people with epilepsy to know when they are at risk of having a seizure.
To mark National Epilepsy Week, the Medication Safety Minute Team in conjunction with Dr Colin Doherty, Epileptologist in St. James’s Hospital, have produced an excellent series of four short videos to highlight the risks associated with sodium valproate (Epilim) if taken during pregnancy.
The term circadian disruption relates to disturbances in a person's "internal body clock" that regulates the 24-hour cycle of biological processes. The transition to daylight saving time (DST - putting the clocks forward for summer) is an annual event that can cause circadian disruption.
On March 22nd, the HSE, Epilepsy Ireland, OACS Ireland, FACS Forum and Trinity College Dublin came together to organise the first National Conference on The Consequences of Sodium Valproate (Epilim) in Trinity College.
GW Pharmaceuticals have announced positive top-line results of a new randomised, double-blind, placebo-controlled Phase 3 clinical trial of Epidiolex in the treatment of seizures associated with Tuberous Sclerosis Complex (TSC).
A Phase 3 study presented at the American Academy of Neurology's Annual Meeting in Philadelphia has provided new evidence of the benefits of pharmaceutical-grade cannabidiol (Epidiolex) in treating Dravet Syndrome. Dravet Syndrome is an infantile onset developmental and epileptic encephalopathy associated with drug-resistant seizures.
Epilepsy Ireland has been made aware of reports of difficulties with the supply of Frisium (Clobazam) 10 mg tablets recently. We have contacted the Irish Pharmaceutical Union and also the Health Products Regulation Authority to clarify what the position is currently.
There had been a delay with production of Frisium which led to stock being made available on a case by case basis in Ireland by the manufacturers Sanofi.